BOC Sciences Blog

What are the functions of Rapamycin? (II)

What are the functions of Rapamycin? (II)

PLoS Biol: Scientists reveal new mechanism of Rapamycin. doi: 10.1371 / journal.pbio.3000252 Recently, in a research report published in PLoS Biology, scientists from the University of Michigan revealed a new […]

What are the functions of Rapamycin? (I)

What are the functions of Rapamycin? (I)

Rapamycin (RAPA), also known as “sirolimus”, was first discovered by scientists in the soil of Easter Island, Chile in 1975 due to its strong antifungal properties. Rapamycin is a macrolide […]

Durvalumab and Pabolizumab for lung cancer treatment

Durvalumab and Pabolizumab for lung cancer treatment

Small cell lung cancer (SCLC) is a rapidly developing, invasive lung cancer that accounts for about 15% of all lung cancer cases. Among them, about three-quarters of patients with small […]

PROTAC technology: Small molecule drug research and development mass murderer is coming! (Ⅱ)

PROTAC technology: Small molecule drug research and development mass murderer is coming! (Ⅱ)

Protein degradation targeted chimera (PROTAC) PROTAC technology began in 2001 that uses the ubiquitin-proteasome system (UPS), the intracellular “cleaner” for cleaning up denatured, mutated, or harmful proteins in cells. PROTAC, which uses […]

PROTAC technology: Small molecule drug research and development mass murderer is coming! (Ⅰ)

PROTAC technology: Small molecule drug research and development mass murderer is coming! (Ⅰ)

Preface Judging from the global drug sales trend in recent years, biological drugs have begun to become popular, while sales of small molecular drugs are declining. Innovations in research and […]

Valedia-Five kinds of plant extracts

Valedia-Five kinds of plant extracts

Pre-diabetes is an increasingly common public health problem that has been recognized by international organizations such as the World Health Organization, the American Diabetes Association, and the International Diabetes Federation. […]

New drug for alopecia areata

New drug for alopecia areata

Concert Pharma recently released the results of its phase II clinical trial evaluating the dose range of the experimental deuterated CTP-543 for patients with moderate to severe alopecia areata, an […]

“Opportunities and Challenges” in the development of the HDACs drugs for cancers

“Opportunities and Challenges” in the development of the HDACs drugs for cancers

Despite the popularity in the development of histone deacelytase (HDAC) inhibitors, the indications of the five already approved HDAC inhibitor drugs on the market are limited to peripheral T-cell lymphoma […]

PD-L1

PD-L1

Introduction Programmed death-ligand 1 (PD-L1) is a protein that is highly expressed on the surface of many cancer cells. As PD-L1’s receptor, PD-1 belongs to the immunoglobulin superfamily and can […]

Osimertinib was approved for first-line treatment

Osimertinib was approved for first-line treatment

The third-generation EGFR inhibitor, Osimertinib (Tagrisso, AZD9291), was approved by the Chinese Food and Drug Administration (NMPA) recently for first-line treatment of patients with EGFR mutation-positive advanced or metastatic non-small cell lung […]